People with trauma histories have an increased odds of cannabis use. Little is known about the frequency or consequences of different cannabis use regimens in cannabis users with trauma histories. Individuals with anxiety disorders tend to administer benzodiazepines in a pro re nata (PRN; i.e., as needed) as opposed to regularly scheduled (RS, e.g., twice daily [BID], three times daily [TID]) manner. Although physicians tend to prescribe benzodiazepines on a PRN regimen to minimize use, this regimen is paradoxically associated with greater use levels. Indeed, PRN administration regimens may increase use via negative reinforcement processes. We extended this older benzodiazepine literature to cannabis by examining regimen of cannabis use among 94 trauma-exposed cannabis users (mean age = 35.1 years; 52.1 % male; 23.4 % with cannabis prescription). Participants reported their initial and current cannabis use regimen (PRN vs. RS vs. both ['PRN+']) and their past month cannabis use frequency (use occasions in last month) and quantity (grams/use occasion). Consistent with patterns in benzodiazepine research, PRN (47.1 % of sample) and PRN+ (43.5 % of sample) were more common than RS regimens (9.4 % of sample). Also consistent with patterns seen with benzodiazepines, our sample moved toward PRN regimens from initial to current use: e.g., 100 % of initial RS users switched to a regimen that included PRN use. Consistent with predictions emerging from learning theory, PRN and PRN+ cannabis users reported significantly higher cannabis use frequencies compared to RS users (p's < 0.01). Unexpectedly, there were no significant differences between cannabis use regimen groups for quantity of cannabis/occasion. While limited by their cross-sectional nature, with longitudinal replication, result may have implications for identifying cannabis use regimens that minimize frequency of use and thereby reduce risk for negative health outcomes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.addbeh.2024.108203 | DOI Listing |
Hum Psychopharmacol
January 2025
School of Psychological Science, Oregon State University, Corvallis, Oregon, USA.
Objective: Despite the popular public perception that cannabis use may be beneficial for relieving mental health symptoms, the empirical evidence remains equivocal. Various legal hurdles limit the ability to research whether acute high-potency cannabis use affects mental health-related processes. Therefore, the current study used a novel methodology to examine the acute effects of high-potency cannabis flower on emotion regulation.
View Article and Find Full Text PDFJ Rural Health
January 2025
Drug Use & Behavior Lab, Department of Health Behavior, School of Public Health, University of Alabama at Birmingham, Birmingham, USA.
Background: Recent legislative initiatives in the United States have focused on the medical and legal status of psychedelics, prompting interest in understanding public perceptions of their risks. This study investigates rural-urban differences in the perception of LSD and cannabis risks using national survey data.
Methods: Data from the National Survey of Drug Use and Health (NSDUH) between 2015 and 2021 were analyzed.
J Subst Use Addict Treat
December 2024
College of Social Work, University of Kentucky, United States of America.
Background: Two scientific and clinical challenges for treating cannabis use disorder (CUD) are developing efficacious treatments with high likelihood of uptake and scalability, and testing the clinical mechanisms by which treatments work. Because young adults experience more CUD than other age groups, a need exists to test the efficacy and hypothesized causal pathways of novel treatments for CUD. Text-delivered treatments have the potential to reach young adults by increasing access and perceived privacy.
View Article and Find Full Text PDFToxicol Appl Pharmacol
December 2024
Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 3, 775 15 Olomouc, Czech Republic. Electronic address:
Cannabidiol (CBD) is a phytocannabinoid from Cannabis sativa L., in which there is currently growing interest for medicinal use. Here, we focused on the safety and pharmacokinetics of a CBD-rich (77 %, w/w) full-spectrum hemp extract in male and female rats.
View Article and Find Full Text PDFInt J Drug Policy
December 2024
Peter Boris Centre for Addictions Research, St. Joseph's Healthcare Hamilton and McMaster University, Canada; Michael G. DeGroote Centre for Medicinal Cannabis Research, McMaster University and St. Joseph's Healthcare Hamilton, Canada.
Background: Recreational cannabis legalization marked a significant policy shift in Canada, but has been difficult to evaluate because of the absence of a control group. Although it is unfeasible to evaluate legalization using a randomized controlled trial design, sophisticated statistical techniques can employ quasi-experimental designs using natural experiments. This study evaluates the impact of cannabis legalization in a longitudinal cohort of Canadian emerging adults by comparing changes in cannabis use frequency and related consequences over time to changes in a similar cohort in a United States jurisdiction where no policy change took place.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!